within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD02_Pertuzumab;

model Pertuzumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FD02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FD02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pertuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). It is primarily used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. Pertuzumab is approved for clinical use and is part of the standard of care in HER2-positive breast cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from population pharmacokinetic analysis, adult cancer patients (mainly breast cancer), mostly female, typical clinical dosing.</p><h4>References</h4><ol><li><p>Tan, AR, et al., &amp; Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>The Lancet. Oncology</i> 22(1) 85–97. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(20)30536-2&quot;>10.1016/S1470-2045(20)30536-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33357420/&quot;>https://pubmed.ncbi.nlm.nih.gov/33357420</a></p></li><li><p>Luo, Y, et al., &amp; Xu, B (2019). Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-cancer drugs</i> 30(8) 866–872. DOI:<a href=&quot;https://doi.org/10.1097/CAD.0000000000000808&quot;>10.1097/CAD.0000000000000808</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31305270/&quot;>https://pubmed.ncbi.nlm.nih.gov/31305270</a></p></li><li><p>Yang, J, et al., &amp; Hu, W (2022). HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 36(3) 393–409. DOI:<a href=&quot;https://doi.org/10.1007/s40259-022-00534-w&quot;>10.1007/s40259-022-00534-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35594017/&quot;>https://pubmed.ncbi.nlm.nih.gov/35594017</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Pertuzumab;
